

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/209697 A9

(43) International Publication Date
07 December 2017 (07.12.2017)

WIPO | PCT

- (51) **International Patent Classification:**
C12Q 1/68 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- (21) **International Application Number:**
PCT/SG2017/050284 **Declarations under Rule 4.17:**
— of inventorship (Rule 4.17(iv))
- (22) **International Filing Date:**
05 June 2017 (05.06.2017) **Published:**
— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/345,081 03 June 2016 (03.06.2016) US **(48) Date of publication of this corrected version:**
20 December 2018 (20.12.2018)
- (71) **Applicant: SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singapore 168753 (SG). **(15) Information about Correction:**
see Notice of 20 December 2018 (20.12.2018)
- (72) **Inventors: IYER, Narayanan Gopalakrishna;** c/o National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG). **TAN, Daniel Shao-Weng;** c/o National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG).
- (74) **Agent: SPRUSON & FERGUSON (ASIA) PTE LTD;** P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** GENETIC ALTERATION IN ANTISENSE LONG NON-CODING RNA AS A BIOMARKER FOR SUSCEPTIBILITY TO DISEASE TREATMENT

(57) **Abstract:** The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding RNA (lncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a method of treating a subject suffering from cancer, who was shown to have a genetic alteration in lncRNA that resides in an antisense strand of an oncogene.



WO 2017/209697 A9